Literature DB >> 33802339

Genotyping and Characterization of HPV Status, Hypoxia, and Radiosensitivity in 22 Head and Neck Cancer Cell Lines.

Eva-Leonne Göttgens1,2, Marleen Ansems1, William P J Leenders3, Johan Bussink1, Paul N Span1.   

Abstract

To study head and neck squamous cell carcinomas (HNSCC) in vitro, a large variety of HNSCC cell lines have been developed. Here, we characterize a panel of 22 HNSCC cell lines, thereby providing a tool for research into tumor-specific treatment options in HNSCC. Both human papillomavirus (HPV) positive and HPV negative tumor cell lines were collected from commercial and collaborative sources. Short tandem repeat profiling was used to confirm or characterize the identity of the cell lines. Targeted sequencing was performed using a standard pathology single molecule Molecular Inversion Probe panel to detect mutations for 23 tumor suppressors and oncogenes. HPV status, p16 status, radiosensitivity data, and hypoxia data are summarized from all cell lines. We detected HPV transcripts in five cell lines, all of which overexpressed p16. One HPV negative cell line was also p16 positive. We detected mutations in KIT (SCCNij185), PIK3CA (SCCNij185), and CDKN2A (UT-SCC-5 and UT-SCC-38). TP53 mutations were the most frequent, occurring in 16/22 cell lines. HPV infection and TP53 mutations were almost mutually exclusive, with the exception of 93-VU-147T. The cell lines exhibited a wide range of sensitivities towards hypoxia and irradiation. Here, we provide a description of a set of frequently used HNSCC cell lines with diverse characteristics as found in HNSCC patients.

Entities:  

Keywords:  head and neck squamous cell carcinoma; mutations; radiosensitivity

Year:  2021        PMID: 33802339      PMCID: PMC7959143          DOI: 10.3390/cancers13051069

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  55 in total

Review 1.  Head and neck squamous cell carcinoma cell lines: established models and rationale for selection.

Authors:  Charles J Lin; Jennifer R Grandis; Thomas E Carey; Susanne M Gollin; Theresa L Whiteside; Wayne M Koch; Robert L Ferris; Stephen Y Lai
Journal:  Head Neck       Date:  2007-02       Impact factor: 3.147

2.  Different mutation profiles associated to P53 accumulation in colorectal cancer.

Authors:  Ignacio López; Ligia P Oliveira; Paula Tucci; Fernando Alvarez-Valín; Renata A Coudry; Mónica Marín
Journal:  Gene       Date:  2012-02-21       Impact factor: 3.688

3.  Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells.

Authors:  T Soukka; M Salmi; H Joensuu; L Häkkinen; P Sointu; L Koulu; K Kalimo; P Klemi; R Grénman; S Jalkanen
Journal:  Cancer Res       Date:  1997-06-01       Impact factor: 12.701

4.  Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells.

Authors:  Brita Singers Sørensen; Morten Busk; Nadine Olthof; Ernst-Jan Speel; Michael R Horsman; Jan Alsner; Jens Overgaard
Journal:  Radiother Oncol       Date:  2013-08-13       Impact factor: 6.280

5.  Inhibition of CDK4/CDK6 Enhances Radiosensitivity of HPV Negative Head and Neck Squamous Cell Carcinomas.

Authors:  Eva-Leonne Göttgens; Johan Bussink; Katarzyna B Leszczynska; Hans Peters; Paul N Span; Ester M Hammond
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-07-02       Impact factor: 7.038

6.  p53 mutations associated with increased sensitivity to ionizing radiation in human head and neck cancer cell lines.

Authors:  K Servomaa; A Kiuru; R Grénman; K Pekkola-Heino; J O Pulkkinen; T Rytömaa
Journal:  Cell Prolif       Date:  1996-05       Impact factor: 6.831

7.  Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.

Authors:  Rami G Azrak; Shousong Cao; Harry K Slocum; Károly Tóth; Farukh A Durrani; Ming-biao Yin; Lakshmi Pendyala; Wanghai Zhang; Howard L McLeod; Youcef M Rustum
Journal:  Clin Cancer Res       Date:  2004-02-01       Impact factor: 12.531

8.  Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.

Authors:  Barbara Burtness; Kevin J Harrington; Richard Greil; Denis Soulières; Makoto Tahara; Gilberto de Castro; Amanda Psyrri; Neus Basté; Prakash Neupane; Åse Bratland; Thorsten Fuereder; Brett G M Hughes; Ricard Mesía; Nuttapong Ngamphaiboon; Tamara Rordorf; Wan Zamaniah Wan Ishak; Ruey-Long Hong; René González Mendoza; Ananya Roy; Yayan Zhang; Burak Gumuscu; Jonathan D Cheng; Fan Jin; Danny Rischin
Journal:  Lancet       Date:  2019-11-01       Impact factor: 79.321

9.  ACLY (ATP Citrate Lyase) Mediates Radioresistance in Head and Neck Squamous Cell Carcinomas and is a Novel Predictive Radiotherapy Biomarker.

Authors:  Eva-Leonne Göttgens; Corina Nam van den Heuvel; Monique C de Jong; Johannes Ham Kaanders; William Pj Leenders; Marleen Ansems; Johan Bussink; Paul N Span
Journal:  Cancers (Basel)       Date:  2019-12-07       Impact factor: 6.639

10.  Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.

Authors:  Laura Q M Chow; Robert Haddad; Shilpa Gupta; Amit Mahipal; Ranee Mehra; Makoto Tahara; Raanan Berger; Joseph Paul Eder; Barbara Burtness; Se-Hoon Lee; Bhumsuk Keam; Hyunseok Kang; Kei Muro; Jared Weiss; Ravit Geva; Chia-Chi Lin; Hyun Cheol Chung; Amy Meister; Marisa Dolled-Filhart; Kumudu Pathiraja; Jonathan D Cheng; Tanguy Y Seiwert
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.